Publications by Dr Tryfonia Mainou-Fowler - ePrints

Browsing publications by Dr Tryfonia Mainou-Fowler.

Newcastle Authors	Title	Year
Dr Nicola Sunter Dr Helen Marr Dr Andrew Hall Dr Tryfonia Mainou-Fowler Professor Graham Jackson et al.	Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk	2015
Dr Nicola Sunter Dr Andrew Hall Dr Tryfonia Mainou-Fowler Professor Graham Jackson Professor James Allan et al.	A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia	2014
Dr Rachel Crossland Dr Tryfonia Mainou-Fowler Dr Michal Sieniawski Dr Christopher Bacon Dr Vikki Rand et al.	High BACH2 gene Expression Is an Indicator of Poor Prognosis in Adult Diffuse Large B-Cell Lymphoma Treated with R-CHOP	2014
Dr Rachel Crossland Dr Michal Sieniawski Parimala Saminathan Dr Tryfonia Mainou-Fowler	MicroRNAs are suitable for assessment as biomarkers from formalin-fixed paraffin-embedded tissue, and miR-24 represents an appropriate reference microRNA for diffuse large B-cell lymphoma studies	2013
Dr Rachel Crossland Dr Michal Sieniawski Dr Brian Angus Professor Stephen Proctor Dr Paul Milne et al.	Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B-cell lymphoma patients	2013
Professor Stephen Proctor Dr Jennifer Wilkinson Gillian Watson Dr Helen Lucraft Dr Tryfonia Mainou-Fowler et al.	Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study	2012
Professor Stephen Proctor Dr Jennifer Wilkinson Dr Helen Lucraft Dr Richard McNally Dr Tryfonia Mainou-Fowler et al.	Comparative clinical responses of three chemotherapy schedules (VEPEMB, ABVD, CLVPP) in 175 Hodgkin Lymphoma patients over 60ys evaluated as part of the Shield (Hodgkin elderly) Study	2011
Dr Rachel Crossland Dr Michal Sieniawski Dr Brian Angus Dr Susan Proctor Kate McCabe et al.	Mature microRNAs of the miR-17-92 cluster predict for disease outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with CHOP-R immunochemotherapy	2011
Dr Tryfonia Mainou-Fowler Dr Gordon Strathdee	Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia	2011
Dr Rachel Crossland Dr Kim Pearce Dr Nicola Sunter Dr Tryfonia Mainou-Fowler	MicroRNAs in B-cell chronic lymphocytic leukaemia (B-CLL): mature microRNAs of the miR-17-92 cluster predict for treatment free survival (TFS) in patients with B-CLL	2011
Dr sarah Johnson Clark Crawford Dr Evan Mulligan Dr Jonathan Wallis Dr Tryfonia Mainou-Fowler et al.	Mitoxantrone in combination with an inhibitor of DNA-dependent kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia	2011
Dr Rachel Crossland Dr John Anderson Dr Brian Angus Professor Stephen Proctor Dr Stephen Crosier et al.	A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines	2010
Dr Rachel Crossland Dr John Anderson Dr Brian Angus Professor Stephen Proctor Dr Stephen Crosier et al.	A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines	2010
Dr Rachel Crossland Professor Stephen Proctor Dr Brian Angus Dr Stephen Crosier Dr John Anderson et al.	A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines	2010
Dr Nicola Sunter Dr Andrew Hall Dr Tryfonia Mainou-Fowler Professor Graham Jackson Professor James Allan et al.	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk	2010
Dr Rachel Crossland Professor Stephen Proctor Professor James Allan Dr Tryfonia Mainou-Fowler	Mature MicroRNAs Mir-18,-19a,-19b,-17-5p and-92 of the Mir-17-92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia	2010
Dr sarah Johnson Dr Tryfonia Mainou-Fowler Professor barbara Durkacz Dr Elaine Willmore	Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: A potential therapy for poor risk B-cell chronic lymphocytic leukaemia	2010
Professor James Allan Dr Nicola Sunter Dr Andrew Hall Dr Christopher Bacon Jonathan Pointon et al.	Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia	2010
Dr Michal Sieniawski Dr Malcolm Farrow Elaine Zhao Dr Jennifer Wilkinson Dr Tryfonia Mainou-Fowler et al.	A Novel Bayesian Prognostic Index for Diffuse Large B-Cell Lymphoma: A New Powerful Tool for Prediction Of Outcome	2009
Dr John Anderson Lynne Overman Dr Katrina Wood Professor Stephen Proctor Dr Stephen Crosier et al.	Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics	2009
Professor James Allan Dr Nicola Sunter Dr Andrew Hall Dr Tryfonia Mainou-Fowler Professor Graham Jackson et al.	A Common Genetic Variant in the 3'UTR of IRF4/MUM1 Associates with Risk of Disease and Poor Prognosis in Chronic Lymphocytic Leukaemia	2008
Dr Nicola Sunter Dr Andrew Hall Dr Tryfonia Mainou-Fowler Professor Graham Jackson Professor James Allan et al.	A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia	2008
Dr Tryfonia Mainou-Fowler Lynne Overman Dr Katrina Wood Dr Brian Angus Professor Stephen Proctor et al.	A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2	2008
Dr Tryfonia Mainou-Fowler Professor Stephen Proctor Dr John Anderson	CD31 density is a new risk factor for patients with B-cell chronic lymphocytic leukaemia	2008
Dr Tryfonia Mainou-Fowler Dr John Anderson Professor Stephen Proctor	CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia	2008
Dr Elaine Willmore Dr sarah Johnson Dr Tryfonia Mainou-Fowler Professor Graham Jackson Dr Celine Cano et al.	DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia	2008
Dr Elaine Willmore Dr sarah Johnson Clark Crawford Dr Tryfonia Mainou-Fowler Professor Graham Jackson et al.	DNA-Dependent Protein Kinase Is a Therapeutic Target in Poor Prognosis B-Cell Chronic Lymphocytic Leukemia	2008
Dr Michal Sieniawski Dr Jennifer Wilkinson Dr Anne Lennard Dr Helen Lucraft Dr Tryfonia Mainou-Fowler et al.	Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define Groups of Patients with Different Overall Survival Which Cannot Be Entirely Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population Based Study of the Scotland and Newcastle Lymphoma Group.	2008
Professor Stephen Proctor Dr Jennifer Wilkinson Dr Tryfonia Mainou-Fowler Dr Michal Sieniawski Dr Katrina Wood et al.	SHIELD - Study of Hodgkin lymphoma in the elderly/lymphoma data base: Progress report	2008
Dr Michal Sieniawski Dr Tryfonia Mainou-Fowler Dr Jennifer Wilkinson Dr John Davison Professor Graham Jackson et al.	The effect of Diffuse Large B-Cell Lymphoma (DLBCL) treatment regimens on survival: a prospective cohort study [Poster]	2008
Dr Tryfonia Mainou-Fowler Lynne Overman Dr Katrina Wood Dr Stephen Crosier Dr Brian Angus et al.	A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2	2007
Dr Tryfonia Mainou-Fowler Professor Stephen Proctor	CD31 density is inversely related to CD38 expression and predicts for disease outcome in patients with B-cell chronic lymphocytic leukaemia (B-CLL)	2006
Dr Tryfonia Mainou-Fowler Jean Norden Dr Peter Middleton Professor Stephen Proctor Professor Anne Dickinson et al.	CD31 expression and gene polymorphisms in patients with B-cell chronic lymphocytic leukemia (B-CLL)	2006
Dr Tryfonia Mainou-Fowler Dr Brian Angus Professor Stephen Proctor Dr Penelope Taylor Dr Katrina Wood et al.	Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL)	2006
Dr Elaine Willmore Professor Graham Jackson Dr Tryfonia Mainou-Fowler Professor Caroline Austin Professor barbara Durkacz et al.	Sensitisation of B-CLL cells to chlorambucil and fludarabine via inhibition of the DNA damage sensor proteins, DNA-PK and ATM	2006
Dr Elaine Willmore Dr Tryfonia Mainou-Fowler Professor Graham Jackson Professor barbara Durkacz	Targeting DNA-PK and ATM increases sensitivity to chlorambucil and fludarabine in chemoresistant and p53-defective B-CLL cells	2006
Professor Stephen Proctor Dr Brian Angus Dr Katrina Wood Dr Tryfonia Mainou-Fowler	Microvessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PDEGF) in classical Hodgkin lymphoma (HL)	2005
Dr John Anderson Dr Stephen Crosier Lynne Overman Dr Tryfonia Mainou-Fowler Dr Sarah Fordham et al.	Survivin in diffuse large B cell lymphoma: Evaluation as a prognostic marker	2005
Dr Tryfonia Mainou-Fowler Professor Stephen Proctor Dr Penelope Taylor	Interleukin 4 production by peripheral blood lymphocytes in patients with classical Hodgkin lymphoma	2004
Dr Tryfonia Mainou-Fowler Professor Stephen Proctor	The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL)	2004
Dr Tryfonia Mainou-Fowler Dr Penelope Taylor Professor Anne Dickinson Professor Stephen Proctor	Intracellular cytokine profiles by peripheral blood CD3(+) T-cells in patients with classical Hodgkin lymphoma	2003
Dr Tryfonia Mainou-Fowler Dr Penelope Taylor Professor Anne Dickinson Dr Peter Saunders Professor Stephen Proctor et al.	Quantification improves the prognostic value of CD38 expression in B cell chronic lymphocytic leukaemia (BCLL)	2001
Dr Tryfonia Mainou-Fowler Professor Stephen Proctor Professor Anne Dickinson	Apoptotic activity of gamma linolenic acid (GLA) on normal and malignant cells in B cell chronic lymphocytic leukaemia (BCLL)	1998
Dr Tryfonia Mainou-Fowler	Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia	1996
Dr Tryfonia Mainou-Fowler	Effect of anti-apolipoprotein-1 on spontaneous apoptosis of B cells in chronic lymphocytic leukaemia: the role of bcl-2 and interleukin 4	1995
Dr Tryfonia Mainou-Fowler	Effects of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells	1995
Dr Tryfonia Mainou-Fowler	Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitrop independently of bcl-2 expression and is inhibited by IL-4	1994
Dr Tryfonia Mainou-Fowler	Effect of interleukin 4 (IL4) and dexamethasone on the apoptosis and bcl-2 expression in B chronic lymphocytic leukaemia (B-CLL) in culture.	1993
Dr Tryfonia Mainou-Fowler	Tumour-associated profiferative responses in vitro of regional lymph node draining solid cancers in man.	1989
Dr Tryfonia Mainou-Fowler	Virulence of L monocytogenes genotypes: course of infection in genetically resistant and susceptible mice.	1988
Dr Tryfonia Mainou-Fowler	Transferrins and defence against infection	1987
Dr Tryfonia Mainou-Fowler	Evidence that transferrin may function exclusively as an iron donor in promoting lymphocytee proliferation	1986
Dr Tryfonia Mainou-Fowler	Iron and immunity	1986
Dr Tryfonia Mainou-Fowler	Effect of iron deficiency on the response of mouse lymphocytes to ConA: the importance of tranferrin-bound iron	1985
Dr Tryfonia Mainou-Fowler	The role of iron and transferrinb in lymphocyte transformation.	1983